FIGURE 1.

Longest Period of Consecutive Opioid Abstinence in the Intervention Phase Among Patients Who Received Placebo or Clonidine in Addition to Buprenorphine^a

^a Each circle represents a single participant’s longest period of abstinence during the intervention phase (weeks 9–20, following a 2-week induction phase; the induction phase followed a 6-week baseline period of buprenorphine treatment alone). Horizontal bars show the group means. The clonidine group maintained continuous abstinence longer than the placebo group (p≤0.05).